Therascreen EGFR Mutation Detection Kit RGQ regulatory update

The U.K.'s NICE issued guidance recommending the use of 5 diagnostics methods, including 2 tests to detect EGFR mutations in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC). NICE backed the cobas EGFR Mutation Test from Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) and the therascreen EGFR RGQ PCR Kit from Qiagen along with 3 sequencing methods. ...